Achieve Life Sciences (ACHV) Change in Interest Receivables (2012 - 2017)
Achieve Life Sciences (ACHV) posted Change in Interest Receivables of -$32000.0 for Q1 2017, down 700.0% on a QoQ basis from -$4000.0 in Q4 2016, and up 44.83% year-over-year from -$22095.2 in Q1 2016.
Achieve Life Sciences (ACHV) Change in Interest Receivables (2012 - 2017) Analysis & Trends
Achieve Life Sciences' Change in Interest Receivables history runs 6 years deep, the most recent figure standing at -$32000.0 for Q1 2017.
- Quarterly Change in Interest Receivables rose 44.83% year-over-year to -$32000.0 in Q1 2017, while the trailing twelve-month figure through Jun 2017 was -$47000.0 (down 62.07% YoY) and the FY2016 annual result came in at -$79000.0, down 3850.0% from the prior year.
- Change in Interest Receivables was -$32000.0 for Q1 2017 at Achieve Life Sciences, down from -$4000.0 in the prior quarter.
- Across five years, Change in Interest Receivables topped out at $94000.0 in Q4 2014 and bottomed at -$166000.0 in Q2 2014.
- A 5-year average of -$19235.3 and a median of -$11000.0 in 2016 frame the typical range for Change in Interest Receivables.
- Peak annual rise in Change in Interest Receivables reached 480.0% in 2014, while the deepest fall reached 766.67% in 2014.
- Achieve Life Sciences' Change in Interest Receivables stood at -$77000.0 in 2013, then soared by 222.08% to $94000.0 in 2014, then slumped by 32.98% to $63000.0 in 2015, then slumped by 106.35% to -$4000.0 in 2016, then sank by 700.0% to -$32000.0 in 2017.
- Business Quant data shows ACHV's Change in Interest Receivables at -$32000.0 in Q1 2017, -$4000.0 in Q4 2016, and -$11000.0 in Q3 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Interest Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -266,893.98 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Achieve Life Sciences | 326.16 Mn | 326.16 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2017 | -32,000.00 |
| Dec 31, 2016 | -4,000.00 |
| Sep 30, 2016 | -11,000.00 |
| Jun 30, 2016 | -6,000.00 |
| Mar 31, 2016 | -58,000.00 |
| Dec 31, 2015 | 63,000.00 |
| Sep 30, 2015 | -28,000.00 |
| Jun 30, 2015 | 5,000.00 |
| Mar 31, 2015 | -42,000.00 |
| Dec 31, 2014 | 94,000.00 |
| Sep 30, 2014 | 19,000.00 |
| Jun 30, 2014 | -166,000.00 |
| Mar 31, 2014 | -52,000.00 |
| Dec 31, 2013 | -77,000.00 |
| Sep 30, 2013 | -5,000.00 |
| Jun 30, 2013 | -21,000.00 |
| Mar 31, 2013 | -6,000.00 |
| Dec 31, 2012 | -180,000.00 |
| Sep 30, 2012 | 35,000.00 |
| Jun 30, 2012 | 100,000.00 |